Table 2.
Treatment Characteristics
| All | RRT | Control | P a | |
|---|---|---|---|---|
| n | 366 | 71 | 295 | |
| Colistin | 48 (13) | 23 (32) | 25 (8) | <.0001 |
| Tigecycline | 117 (32) | 22 (30) | 95 (32) | .88 |
| Amikacin | 58 (16) | 13 (18) | 45 (15) | .59 |
| Gentamicin | 65 (18) | 12 (17) | 53 (18) | 1.0 |
| Trimethoprim/sulfamethoxazole | 37 (10) | 9 (13) | 28 (9) | .39 |
| Carbapenem | 130(36) | 31 (44) | 99 (34) | .13 |
| Fosfomycinb | 16 (4) | 1 (1) | 15 (5) | .33 |
| Ceftazidime/avibactam | 28 (8) | 3 (4) | 25 (8) | .32 |
| Antibiotics without in vitro anti-CRE activity | 62 (17) | 11 (15) | 51 (17) | .86 |
| None of above | 22 (7) | 2 (3) | 20 (7) | .59 |
All data expressed as n (%), unless otherwise indicated. Shown is the number of patients who received a given antibiotic in the 14 days following index culture. Percentages accumulated exceed 100% as patients may have received more than 1 antibiotic.
Abbreviations: CRE, carbapenem-resistant Enterobacteriaceae; RRT, renal replacement therapy.
aUnivariable relationship between variable of interest and RRT.
bFosfomycin use was only recorded in patients with urinary tract infections.